Clinical Trials Logo

Refractory Cutaneous Melanoma clinical trials

View clinical trials related to Refractory Cutaneous Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05200143 Active, not recruiting - Clinical trials for Refractory Cutaneous Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Start date: June 8, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.

NCT ID: NCT03420963 Recruiting - Clinical trials for Refractory Malignant Solid Neoplasm

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Start date: August 31, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Drugs used in chemotherapy, such as cyclophosphamide and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NK cells together with cyclophosphamide and etoposide may work better in treating children and young adults with solid tumors.